Navigation Links
Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Date:11/11/2008

compared to placebo. Also, HDL function was significantly improved in Hp2-2 individuals who took vitamin E, compared to placebo. Following the study, it was discovered that in those Hp2-2 individuals who had received vitamin E, the incidence of MI after stopping vitamin E treatment significantly increased (0.4 percent on vitamin E vs. 1.8 percent off vitamin E, p=0.03). However, only two months after vitamin E withdrawal, HDL function had deteriorated to its level of dysfunction prior to the initiation of the study. Furthermore, in the 15-month period following the termination of the study, there was little demonstrable difference in the incidence of MI in those Hp2-2 individuals who had received vitamin E and stopped taking it after the end of the study compared to those who received placebo (1.8 percent vitamin E vs. 1.7 percent placebo, p=0.9).

About Hp2-2 Diabetes

The best understood function of haptoglobin, a common serum protein, is to bind free hemoglobin released from red blood cells. Extracellular hemoglobin (hemoglobin not found in red blood cells) is a potent oxidizing agent capable of inflicting oxidative tissue damage. Haptoglobin binds to this extracellular hemoglobin and inhibits hemoglobin induced oxidation. Once hemoglobin is bound to haptoglobin, it is rapidly cleared from the bloodstream by the liver or specialized white blood cells.

Haptoglobin in humans exists as three different proteins that arise from one of three haptoglobin gene combinations in the population, Hp 1-1 (16%), Hp2-2 (36%) and Hp1-2 (48%) For a variety of reasons that are well described in medical literature, Hp2-2 is more effective than Hp1-1 at preventing hemoglobin-induced oxidation in the bloodstream and blood vessel wall.

As a result, scientists have determined that the rate of heart disease is five times higher in Hp2-2 diabetes than in Hp1-1 diabetes. Hp2-2 diabetes also has higher rates of myocardial infarction and re-vascularization within o
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
4. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
5. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
6. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
10. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
11. Synvista Therapeutics to be Featured on Wallst.net
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a biopharmaceutical ... genetic deficiencies that result in metabolic disorders, announced today ... S-1 with the U.S. Securities and Exchange Commission (SEC) ... of its common stock. The number of shares to ... have not yet been determined. Citigroup and ...
(Date:8/27/2014)... nature,s mysteries is how plants survive impact by ... sun,s rays, while using this energy for photosynthesis. ... the plant,s blades quickly dissipate the energy throughout ... Researchers at DTU Physics have now managed to ... and bacteria contain light-absorbing proteins which play a ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014  Lisa Kulik ... years this July 4 holiday, thanks to a groundbreaking ... Ph.D., an internationally renowned clinician-researcher at the University of ... a 55-year-old Peoria, Ariz. resident ... robs its victims of sight. On June 2, she ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2DTU researchers film protein quake for the first time 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... QIAGEN (Nasdaq: QGEN , Frankfurt: QIA), which ... States offices in five locations, brought on board its ... as a symbol of the biotech company,s continued strong ... both in the U.S. and abroad. QIAGEN is the ...
... Phase 3 Combination Rule Trial for NDA Submission , ... BEDMINSTER, N.J., Dec. 15 QRxPharma Limited (ASX: QRX ... on the development and commercialization of therapies for pain ... of a comparative study to evaluate the efficacy and ...
... Inc. (Amex: ANX ), a biopharmaceutical company ... primarily for the treatment of cancer, today announced that ... the sale or disposition of one or more of ... other transactions that maximize the value of Company,s assets. ...
Cached Biology Technology:QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations 2QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations 3QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations 4QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy 2QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy 3ADVENTRX Exploring Strategic Options 2ADVENTRX Exploring Strategic Options 3ADVENTRX Exploring Strategic Options 4
(Date:8/27/2014)... A growing number of consumers are willing to pay ... "organic", but whether they,re getting what the label claims ... tomatoes are devising a new way to make sure ... appears in ACS, Journal of Agricultural and Food ... Researchers from the Bavarian Health and Food Safety Authority ...
(Date:8/27/2014)... lost or abandoned each year in U.S. waters and ... to catch fish, crabs, and other species such as ... and the watermen who depend on the resources--losses that ... study. , The report, published in the Marine ... to examine the derelict fish trap problem, and so-called ...
(Date:8/27/2014)... main factors thought to be associated with outcomes ... the age of the patient, mechanism of injury, ... repair method, operation technique, and repair materials. However, ... of peripheral nerve injuries, there is no agreement ... and the dose-effect relationship of the predictors has ...
Breaking Biology News(10 mins):NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... Researchers using an extremely fast and accurate imaging technique have ... shuttle material within living cells. The motors cooperate in a ... tug of war many scientists had imagined. , "We ... do not compete for control, even though they want to ...
... Yale, in collaboration with NIH researchers, have identified a ... system for detection of parasitic infections, leading the way ... , Published in the April 28 issue of Science ... parasites interface with the immune system--a problem of great ...
... from the first clinical trial of a therapeutic cancer ... (ProMuneTM, Coley Pharmaceutical), with a peptide antigen were reported ... shows that the CpG 7909 DNA sequence is safe, ... destroy cancer cells. The Phase I study was conducted ...
Cached Biology News:Molecular Motors Cooperate In Moving Cellular Cargo, Study Shows 2Yale researchers identify molecule for detecting parasitic infection in humans 2Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy 2
... Second Mitochondria Derived Activator of ... 20 mM HEPES, pH 7.5 AVOID FREEZE/THAW CYCLES. ... Smac/DIABLO with a carboxy terminal His•Tag ® ... E. coli . Smac/DIABLO is released along with ...
...
... Fixed clamp trays and universal ... Magnetic drive Shaking ... 25 mm amplitude ... to 2000 ml, including Fernbach flasks ...
... the NEW VSOS-4P, all Programmable and Digital Orbital ... now been redesigned to make every day use ... Programmable memory for up to 4 different programs. ... of your program. Furthermore, the VSOS-4P has a ...
Biology Products: